Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Chanan-Khan A, et al. Among authors: miller kc. Leuk Lymphoma. 2009 Jul;50(7):1096-101. doi: 10.1080/10428190902912460. Leuk Lymphoma. 2009. PMID: 19479618 Clinical Trial.
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. Sher T, et al. Among authors: miller kc. Br J Haematol. 2011 Jul;154(1):104-10. doi: 10.1111/j.1365-2141.2011.08703.x. Epub 2011 May 9. Br J Haematol. 2011. PMID: 21554260 Free PMC article. Clinical Trial.
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Masood A, et al. Among authors: miller kc. Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. Epub 2011 Dec 15. Br J Haematol. 2012. PMID: 22171982 Free article. Clinical Trial.
Supportive care in multiple myeloma.
Chanan-Khan A, Miller KC. Chanan-Khan A, et al. Among authors: miller kc. Clin Lymphoma Myeloma. 2006 Jul;7(1):42-50. doi: 10.3816/CLM.2006.n.038. Clin Lymphoma Myeloma. 2006. PMID: 16879769 Review.
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Chanan-Khan A, et al. Among authors: miller kc. J Clin Oncol. 2006 Dec 1;24(34):5343-9. doi: 10.1200/JCO.2005.05.0401. Epub 2006 Nov 6. J Clin Oncol. 2006. PMID: 17088571 Clinical Trial.
119 results